Vertex, J&J and Glaxo collaborating on hepatitis C therapies


Posted on November 1st, by Michael Shapiro-Barr

Vertex Pharmaceuticals Inc. has agreed to test one of its experimental therapies for hepatitis C with other drugs from Johnson & Johnson and GlaxoSmithKline Plc.  Combination therapy has become the most effective approach to combating hepatitis C, due to the fact that the combination of different kinds of drugs will address the various ways the virus infects the body.

Read More





Comments are closed.



From the Blog

$1.2 Billion Medicaid Fraud Penalty Award Reversed and Claim Dismissed in Arkansas Appeal

In another decision narrowing the scope of state Medicaid fraud statutes, on March 20, 2014, the Supreme Court of Arkansas, in Ortho-McNeil-Janssen Pharmaceuticals, Inc....

President Issues Sanctions to Support Stability in Ukraine

Today, March 6, 2014, President Obama signed a new Executive Order in response to the threats Ukraine is facing to its peace and stability....

New Reprint Guidance Maintains Bipartisan Status Quo

On February 28, 2014, the FDA issued its most recent unofficial guidance on distribution by manufacturers of research concerning off-label uses.  With minor textual revisions,...